[go: up one dir, main page]

MX2016008721A - Derivados de aril sultama como moduladores del receptor huerfano relacionado con acido retinoico (rorc). - Google Patents

Derivados de aril sultama como moduladores del receptor huerfano relacionado con acido retinoico (rorc).

Info

Publication number
MX2016008721A
MX2016008721A MX2016008721A MX2016008721A MX2016008721A MX 2016008721 A MX2016008721 A MX 2016008721A MX 2016008721 A MX2016008721 A MX 2016008721A MX 2016008721 A MX2016008721 A MX 2016008721A MX 2016008721 A MX2016008721 A MX 2016008721A
Authority
MX
Mexico
Prior art keywords
sultam derivatives
aryl
rorc modulators
compounds
rorc
Prior art date
Application number
MX2016008721A
Other languages
English (en)
Inventor
Bodil Van Niel Monique
Hurley Christopher
Fauber Benjamin
Rene Olivier
Gaines Simon
Gobbi Alberto
Vesey David
Gancia Emanuela
LADDYWAHETTY Tammy
Winship Paul
Ward Stuart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016008721A publication Critical patent/MX2016008721A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos de la fórmula I: (ver Fórmula) o sales farmacéuticamente aceptables de los mismos, en donde n, p, q, r, X1, X2, X3, X4, Y, Z, A, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 y R13 son como se definen en la presente. También se describen métodos de preparación de los compuestos y el uso de los compuestos para el tratamiento de enfermedades inflamatorias tales como artritis, esclerosis muscular y psoriasis.
MX2016008721A 2014-01-10 2015-01-09 Derivados de aril sultama como moduladores del receptor huerfano relacionado con acido retinoico (rorc). MX2016008721A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925845P 2014-01-10 2014-01-10
US201462091861P 2014-12-15 2014-12-15
PCT/EP2015/050292 WO2015104354A1 (en) 2014-01-10 2015-01-09 ARYL SULTAM DERIVATIVES AS RORc MODULATORS

Publications (1)

Publication Number Publication Date
MX2016008721A true MX2016008721A (es) 2017-01-26

Family

ID=52423686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008721A MX2016008721A (es) 2014-01-10 2015-01-09 Derivados de aril sultama como moduladores del receptor huerfano relacionado con acido retinoico (rorc).

Country Status (9)

Country Link
US (1) US10131644B2 (es)
EP (1) EP3092239B1 (es)
JP (1) JP6458041B2 (es)
KR (1) KR20160106705A (es)
CN (1) CN105899507B (es)
CA (1) CA2935012A1 (es)
MX (1) MX2016008721A (es)
RU (1) RU2016131363A (es)
WO (1) WO2015104354A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620884A (zh) 2014-01-10 2016-06-16 赫孚孟拉羅股份公司 作為ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
HK1250235A1 (zh) * 2015-07-08 2018-12-07 F. Hoffmann-La Roche Ag 作为rorc调节剂的芳基磺内酰胺衍生物
WO2017005668A1 (en) * 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag ARYL SULTAM DERIVATIVES AS RORc MODULATORS
CN114901640A (zh) * 2019-12-24 2022-08-12 兹杜斯生命科学有限公司 适用于治疗血脂异常的新型化合物
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
WO2013064231A1 (en) * 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
US9216988B2 (en) * 2011-12-22 2015-12-22 Genentech, Inc. Benzyl sulfonamide derivatives as RORc modulators
US20130190356A1 (en) * 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
AR092348A1 (es) * 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
HK1211019A1 (en) * 2012-12-10 2016-05-13 F. Hoffmann-La Roche Ag Benzyl sulfonamide derivatives as rorc modulators
EP2928866A1 (en) * 2012-12-10 2015-10-14 F. Hoffmann-La Roche AG BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS
JP2016510781A (ja) * 2013-03-15 2016-04-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＲＯＲｃモジュレーターとしてのアリールスルファミド及びスルファミン酸誘導体
HK1220976A1 (zh) * 2013-06-21 2017-05-19 F. Hoffmann-La Roche Ag 作为rorc调节剂的芳基磺内酰胺衍生物
MX2016008780A (es) * 2014-01-10 2016-09-08 Hoffmann La Roche Derivados de sultam heteroarilo como moduladores del receptor huerfano relacionado con el acido retinoico gamma (ror gamma).
TW201620884A (zh) * 2014-01-10 2016-06-16 赫孚孟拉羅股份公司 作為ＲＯＲｃ調節劑之芳基磺內醯胺衍生物

Also Published As

Publication number Publication date
WO2015104354A1 (en) 2015-07-16
CA2935012A1 (en) 2015-07-16
EP3092239B1 (en) 2019-10-02
US20170137393A1 (en) 2017-05-18
US10131644B2 (en) 2018-11-20
KR20160106705A (ko) 2016-09-12
EP3092239A1 (en) 2016-11-16
RU2016131363A (ru) 2018-02-16
CN105899507B (zh) 2019-06-07
CN105899507A (zh) 2016-08-24
JP2017503808A (ja) 2017-02-02
JP6458041B2 (ja) 2019-01-23

Similar Documents

Publication Publication Date Title
PH12014502788A1 (en) ARYL SULTAM DERIVATIVES AS RORc MODULATORS
MX2016008499A (es) Derivados de arilsultamo como moduladores del receptor huerfano relacionado con el receptor de retinoide (rorc).
MX2016008721A (es) Derivados de aril sultama como moduladores del receptor huerfano relacionado con acido retinoico (rorc).
PH12016501972A1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PH12018502136A1 (en) Heterocyclic amides useful as protein modulators
MX2015006926A (es) Derivados de bencil sulfonamida como moduladores del receptor huerfano relacionado con el receptor retinoide (rorc).
TW201613872A (en) IRAK4 inhibiting agents
ZA201701299B (en) Glycosidase inhibitors
MX2016015247A (es) Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc).
NZ730724A (en) Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1
PH12021551134A1 (en) Oxysterols and methods of use thereof
MX2015011180A (es) Derivados de aril sulfamida y sulfamato como moduladores del receptor huerfano relacionado con el receptor del retinoide (porc).
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MX2017007748A (es) Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk).
NZ712207A (en) Tetrahydropyrrolothiazine compounds
MX2015015614A (es) Derivados de aril sultama como moduladores del receptor huerfano relacionado con el receptor del retinoide (rorc).
UY36226A (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
PH12017500095A1 (en) Imidazopyridazine compounds
PH12020551586A1 (en) Oxysterols and methods of use thereof
MX2016005128A (es) Derivados de 5,6,7,8-tetahidro-5,8-metanocinolina como moduladores del receptor huerfano y relacionado con acido retinoico (rorc) para el tratamiento de enfermedades autoinmunes.
TW201613864A (en) Novel compounds
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
ZA201606471B (en) Antimitotic amides for the treatment of cancer and proliferative disorders
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы